Bookmark

Add to MyYahoo RSS

Watson Pharmaceuticals News

News on Watson Pharmaceuticals (Ticker: WPI) continually updated from thousands of sources around the net.

Monday Jul 14 | Investor's Business Daily

Actavis Fuels Growth With Acquisitions, New Generics

Since closing its acquisition of Forest Laboratories on July 2, when new CEO Brenton Saunders took the helm, Actavis has completed a $1.1 billion purchase of Furiex Pharmaceuticals, and confirmed it filed patent challenges for generic versions of two drugs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Forest Laboratories, Forest Labs, Pharmaceuticals, Ireland, World News, Multiple Sclerosis, Health

Fri Jun 20, 2014

PE Hub

JHL Biotech raises $35 mln Series B funding

Milestone Capital has led a $35 million Series B funding in JHL Biotech, Inc. , a biopharmaceutical company.

Comment?

Related Topix: Science / Technology, Biotech, Venture Capital, Emerging Technology, Startups, Kleiner Perkins Caufield & Byers, Investment Services, Kleiner Perkins Caufield and Byers, Financial Services, Medicine, Pharmaceuticals, Healthcare Industry

Fri May 23, 2014

Investor's Business Daily

Actavis Builds Base As Annual Earnings Keep Growing

The former Watson Pharmaceuticals renamed itself Actavis after buying the latter drugmaker in 2012.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Pharmaceuticals, Warner Chilcott

Fri May 02, 2014

JD Supra

A Prosecution History Without Express Disclaimers Still Informs Claim Construction

Addressing the impact of statements made during prosecution on claim construction, the U.S. Court of Appeals for the Federal Circuit vacated and remanded a lower court's ruling of infringement, finding that the lower court construed relevant terms too broadly in view of the statements made during prosecution.

Comment?

Related Topix: US News, Federal Circuit Court of Appeals, Biotech, Medicine, Pharmaceuticals, Healthcare Industry

Mon Apr 28, 2014

Courthouse News Service

Immunity Denied in AndroGel Monopoly Spat

Drugmakers cannot dismiss antitrust claims stemming from their multimillion-dollar settlements to eliminate competing generic drugs, a federal judge ruled.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Pharmaceuticals, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••